Form D · Pharmaceuticals

NEKTAR THERAPEUTICS

San Francisco, CA · CIK 0000906709

Offering snapshot reported Mar 19, 2024 · SEC filing

Reported sold
$30M
Offering amount: $30M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 4, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 19, 2024Initial$30,000,000No comparison1SEC filing
Apr 3, 2018Initial$849,999,960No comparison1SEC filing
Oct 6, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-508055

Source: Form D, filed Mar 19, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jeff R. Ajer Director
Jeffrey R Ajer Director
Diana M Brainard Director
Robert B Chess Director
Stephen K. Doberstein Executive
Sandra Gardiner Executive
R. Scott Greer Director
Maninder Hora Executive
Christopher A. Kuebler Director
Gil M. Labrucherie Executive
Lutz Lingnau Director
John Nicholson Executive
Howard W Robin Director, Executive
Jillian B. Thomsen Executive
Roy A Whitfield Director
Mark A Wilson Executive
Dennis L. Winger Director
Jonathan Zalevsky Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
455 Mission Bay Boulevard South
San Francisco, CA, 94158